Recombinant Mouse TRANCE/RANKL Protein, Active, Low Endotoxin
Description
Product Overview
| Product Name | Recombinant Mouse TRANCE/RANKL Protein |
| Target Symbol | TNFSF11 |
| Alternative Names | Tumor Necrosis Factor Ligand Superfamily Member 11, TNFSF11, TNF-Related Activation-Induced Cytokine, Osteoclast Differentiation Factor, Receptor Activator Of Nuclear Factor Kappa B Ligand, Tumor Necrosis Factor Ligand 6B, Osteoprotegerin Ligand, TRANCE, RANKL, OPGL, ODF, CD254, HRANKL2 , TNLG6B, OPTB2, SOdf |
| Accession Number | O35235 |
| Expression System | E. coli. |
| Molecular Weight | 19.3 kDa (monomer, predicted) |
| Sequence | Ala144-Asp316 |
| Purity | >96% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining |
| Activity | Determined by an osteoclast differentiation assay using mouse RAW 264.7 cells. The ED50 for this effect is typically 1-10 ng/mL |
| Formulation | Lyophilized from sterile PBS with Trehalose, pH 7.4, without carrier-protein. |
| Endotoxin Level | <0.5 EU per 1 µg of the protein as determined by the LAL method |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. |
| Reconstitution | Reconstitute at 100 ug/mL in sterile PBS. |
| Target Function | TRANCE (TNF-related activation-induced cytokines) also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), is a protein primarily involved in the regulation of bone remodeling and immune function. Its main function is to stimulate the differentiation and activation of osteoclasts. Expression of TRANCE by T cells promotes survival and activation of dendritic cells. Development of the lymph node stromal cells involves TRANCE and regulation of self-tolerance in the thymus also involves TRANCE. Additional functions of TRANCE include: differentiation of lactating mammary epithelial cells, glucose metabolism in the liver, tumorigenesis and metastasis. TRANCE signaling is facilitated through binding its receptor, RANK (CD265). However, Osteoprotegerin (OPG) acts as a decoy receptor for TRANCE, thereby regulating TRANCE-RANK interactions. |
| Tissue Specificity | TRANCE expression has been reported in primarily in lungs, thymus and lymph nodes, and also in bone marrow, stomach, spleen, breast, placenta, heart, thyroid, and skeletal muscle. |
| Cellular Localization | Membrane-bound and cleaved soluble protein forms |
| Involvement In Disease | Dysregulation of TRANCE is related to osteoporosis, rheumatoid arthritis (RA), Paget’s disease (chronic bone disorder characterized by abnormal bone remodeling), bone loss in periodontal disease, vascular calcification, multiple sclerosis (MS), systemic lupus erythematosus (SLE), multiple myeloma, breast cancer, lung cancer and bone metastases of tumors. |
Intended use
Research Use Only
Specifications
| Product information | |
|---|---|
| Catalog number | BEP-0035 |
| Size | 100ug |
Need a different construct, tag or scale?
Our custom recombinant protein production service covers gene synthesis, expression in E. coli, yeast, insect and mammalian cells, purification and QC, for Non-GMP research or GMP manufacturing.